1887
Volume 2014, Issue 2
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

The use of anticoagulant therapy in patients with pulmonary arterial hypertension (PAH) has been controversial for decades. Recommendations for anticoagulation in these patients are often derived from small, retrospective, and single centre studies without any placebo-controlled randomized study. Furthermore, uncertainties exist regarding a number of issues such as patient selection, risk stratification for bleeding, the intensity of anticoagulation, appropriateness of anticoagulation in different types of PAH, and the potential use of new oral anticoagulants.

Recently, the database of the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) has been analyzed to assess the effect of anticoagulation on the long-term outcome of patients with various forms of PAH. This analysis is the largest to date to assess anticoagulant therapy in PAH patients in a prospective design with long observation period. The results of COMPERA lend support to current recommendations for the use of anticoagulant therapy in patients with idiopathic PAH, but not in other forms of PAH. Also, the study confirmed the previously reported concern that anticoagulant therapy may be harmful in patients with scleroderma-associated PAH.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.25
2014-09-01
2019-09-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/2/gcsp.2014.25.html?itemId=/content/journals/10.5339/gcsp.2014.25&mimeType=html&fmt=ahah
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.25
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error